Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.
Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.
Biovigil Hygiene Technologies has developed a device that detects when a medical professional enters a patient's room and subsequently issues an alert if the doctor did not wash their hands after patient care.
Reuters has the "exclusive" this morning that the FDA may approve Merck's PD-1 immuno-oncology superstar pembrolizumab for melanoma some weeks ahead of the October 28 PDUFA date. Then again, they may not, but it's looking good, according to the wire service.
San Francisco-based Kindred Bioscience did not meet the primary endpoint during a trial of CereKin, its drug for canine osteoarthritis, based off studies for Amgen and Pfizer's Enbrel.
Almost exactly one year after Daniel O'Connor was named CEO at Advaxis, he celebrated the personal milestone with the latest in a string of deals. Pharma giant Merck stepped up with a no-strings-attached immuno-oncology development pact for pembrolizumab, one of the hot new checkpoint inhibitors promising a groundbreaking new approach to treating a wide variety of cancers.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
German contract researcher Evotec has signed a deal with Medicines for Malaria Venture, lending its expertise to the nonprofit's efforts to encourage neglected disease R&D around the world.
Startup OncoSynergy is jumping on the crowdfunding bandwagon to raise money to test a drug candidate in its pipeline against the deadly Ebola virus, which has infected 2,473 people and killed 1,350 of those in the worst outbreak of the disease in West Africa.
Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.